Our product candidate, eflornithine, is a novel cytostatic (growth inhibiting) agent, which we are developing for the potential treatment of patients with anaplastic astrocytoma (AA).

Eflornithine irreversibly inhibits production of a key enzyme that can cause tumor growth in certain types of cancer.

The company’s lead product candidate under active development is eflornithine in an oral solution. Orbus Therapeutics is developing eflornithine for the treatment of patients with anaplastic astrocytoma (AA), or Grade 3 glioma, a rare and deadly form of brain cancer.  Eflornithine irreversibly blocks ornithine decarboxylase (ODC), a key enzyme involved in cell division and proliferation associated with various types of cancer.